Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TSBX Stock Forecast 2025-2026
$0.35
Current Price
$8.67M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to TSBX Price Targets
+182.5%
To High Target of $1.00
+182.5%
To Median Target of $1.00
+182.5%
To Low Target of $1.00
TSBX Price Momentum
-2.8%
1 Week Change
+2.9%
1 Month Change
-87.2%
1 Year Change
-30.0%
Year-to-Date Change
-88.4%
From 52W High of $3.05
+22.1%
From 52W Low of $0.29
📊 TOP ANALYST CALLS
Did TSBX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Turnstone Biologics is one of their latest high-conviction picks.
Latest TSBX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, TSBX has a neutral consensus with a median price target of $1.00 (ranging from $1.00 to $1.00). Currently trading at $0.35, the median forecast implies a 182.5% upside. This outlook is supported by 0 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TSBX Analyst Ratings
0
Buy
1
Hold
0
Sell
TSBX Price Target Range
Low
$1.00
Average
$1.00
High
$1.00
Current: $0.35
Latest TSBX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TSBX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 14, 2024 | B of A Securities | Charlie Yang | Neutral | Downgrade | $0.50 |
| Aug 19, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $10.00 |
| Aug 19, 2024 | Piper Sandler | Joseph Catanzaro | Overweight | Maintains | $3.75 |
| Aug 15, 2023 | B of A Securities | Geoff Meacham | Buy | Initiates | $18.00 |
| Aug 15, 2023 | Piper Sandler | Joseph Catanzaro | Overweight | Initiates | $20.00 |
Turnstone Biologics Corp (TSBX) Competitors
The following stocks are similar to Turnstone Biologics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TSBX
Turnstone Biologics
mkt cap
8.25M
Turnstone Biologics Corp (TSBX) Financial Data
Turnstone Biologics Corp has a market capitalization of $8.67M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -126.0%.
Valuation Metrics
Market Cap
$8.67M
Enterprise Value
$-13,099,530
P/E Ratio
0.0x
PEG Ratio
-0.2x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+266.7%
Current Ratio
3.7x
Debt/Equity
3.5x
ROE
-126.0%
ROA
-63.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Turnstone Biologics Corp (TSBX) Business Model
About Turnstone Biologics Corp
What They Do
Develops novel immunotherapies for cancer treatment.
Business Model
The company focuses on researching and advancing oncolytic virus therapies that utilize the immune system to target various cancer types. Turnstone Biologics generates revenue through the development of its clinical and preclinical programs, which aim to provide innovative treatment solutions that differentiate from traditional cancer therapies.
Additional Information
With a diverse pipeline targeting multiple tumor types, Turnstone is positioned to make significant contributions to the oncology sector. Their commitment to pioneering new therapeutic modalities could transform patient outcomes and impact the healthcare and pharmaceutical industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
8
CEO
Dr. Sammy J. Farah M.B.A., Ph.D.
Country
United States
IPO Year
N/A
Website
turnstonebio.comTurnstone Biologics Corp (TSBX) Latest News & Analysis
Latest News
Quick Summary
Turnstone Biologics Corp. (Nasdaq: TSBX) reported Q1 2025 financial results and announced the discontinuation of all TIDAL-01 clinical studies as of January 2025.
Why It Matters
Turnstone's decision to halt TIDAL-01 clinical studies signals a strategic shift, impacting its growth potential and altering investor sentiment on its future profitability and innovation trajectory.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Turnstone Biologics Corp. (Nasdaq: TSBX) reported its Q4 and full-year 2024 financial results and highlighted preclinical data on Selected TIL therapies presented at the SITC Annual Meeting in November 2024.
Why It Matters
Turnstone Biologics' financial results and updates on Selected TIL therapy may influence investor sentiment by highlighting progress in innovative cancer treatments and potential revenue growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), indicating improved earnings outlook which may positively impact the stock price soon.
Why It Matters
The Zacks Rank upgrade to #2 indicates strong earnings potential for Turnstone Biologics, likely boosting investor confidence and driving stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Turnstone Biologics is advancing its Selected TIL technology for solid tumors, with ongoing Phase 1 trials for TIDAL-01. They will present preclinical data at the SITC Annual Meeting, Nov 6-10, 2024.
Why It Matters
Turnstone's advancements in TIL technology and ongoing Phase 1 trials could enhance treatment efficacy for solid tumors, potentially positioning the company favorably in the biotech market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
10 months ago
Quick Summary
Turnstone Biologics (NASDAQ: TSBX) shares are declining following its earnings report, which revealed a diluted EPS of -92 cents.
Why It Matters
Turnstone Biologics’ poor earnings report, showing a -92 cents EPS, signals financial struggles, potentially leading to decreased investor confidence and stock price decline.
Source: InvestorPlace
Market Sentiment:
Negative
Quick Summary
Turnstone Biologics Corp. (TSBX) shares dropped following the release of initial data from its Phase 1 STARLING trial for TIDAL-01 in metastatic microsatellite-stable colorectal cancer.
Why It Matters
Turnstone Biologics' lower stock price reflects investor reaction to disappointing Phase 1 trial results, indicating potential setbacks in drug development and future revenue projections.
Source: Benzinga
Market Sentiment:
Neutral
Frequently Asked Questions About TSBX Stock
What is Turnstone Biologics Corp's (TSBX) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Turnstone Biologics Corp (TSBX) has a median price target of $1.00. The highest price target is $1.00 and the lowest is $1.00.
Is TSBX stock a good investment in 2025?
According to current analyst ratings, TSBX has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.35. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TSBX stock?
Wall Street analysts predict TSBX stock could reach $1.00 in the next 12 months. This represents a 182.5% increase from the current price of $0.35. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Turnstone Biologics Corp's business model?
The company focuses on researching and advancing oncolytic virus therapies that utilize the immune system to target various cancer types. Turnstone Biologics generates revenue through the development of its clinical and preclinical programs, which aim to provide innovative treatment solutions that differentiate from traditional cancer therapies.
What is the highest forecasted price for TSBX Turnstone Biologics Corp?
The highest price target for TSBX is $1.00 from at , which represents a 182.5% increase from the current price of $0.35.
What is the lowest forecasted price for TSBX Turnstone Biologics Corp?
The lowest price target for TSBX is $1.00 from at , which represents a 182.5% increase from the current price of $0.35.
What is the overall TSBX consensus from analysts for Turnstone Biologics Corp?
The overall analyst consensus for TSBX is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $1.00.
How accurate are TSBX stock price projections?
Stock price projections, including those for Turnstone Biologics Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 8:10 AM UTC